Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation

Sub-analysis of the EXPAND Study

Shinichiro Uchiyama, Hirotsugu Atarashi, Hiroshi Inoue, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Hiroaki Shimokawa

研究成果: ジャーナルへの寄稿記事

抄録

The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treated with rivaroxaban (10 mg/day, 43.5%; 15 mg/day, 56.5%) were followed for a mean period of 897.1 ± 206.8 days with a high follow-up rate (99.7%). The primary prevention group comprised patients without history of ischemic stroke or TIA (n = 5546, 77.7%), and the secondary prevention group comprised those with history of ischemic stroke or TIA (n = 1595, 22.3%). In the primary and secondary prevention groups, the incidence rate of stroke or SE (primary efficacy endpoint) was 0.7 and 2.2%/year, respectively (P < 0.001), and the incidence rate of major bleeding (primary safety endpoint) was 1.2 and 1.5%/year, respectively (P = 0.132). For major bleeding events, the incidence rate of intracranial bleeding was 0.4 and 0.8%/year (P = 0.002) in the primary and secondary prevention groups, respectively. This sub-analysis of the EXPAND Study showed that the Japan-specific dosages of rivaroxaban were effective and safe in Japanese NVAF patients with and those without ischemic stroke or TIA in routine clinical practice.

元の言語英語
ページ(範囲)141-150
ページ数10
ジャーナルHeart and Vessels
34
発行部数1
DOI
出版物ステータス出版済み - 1 22 2019

Fingerprint

Primary Prevention
Secondary Prevention
Embolism
Atrial Fibrillation
Stroke
Transient Ischemic Attack
Hemorrhage
Incidence
Japan
Safety
Patient Safety
Observational Studies
Rivaroxaban
Cohort Studies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study. / Uchiyama, Shinichiro; Atarashi, Hirotsugu; Inoue, Hiroshi; Kitazono, Takanari; Yamashita, Takeshi; Shimizu, Wataru; Ikeda, Takanori; Kamouchi, Masahiro; Kaikita, Koichi; Fukuda, Koji; Origasa, Hideki; Shimokawa, Hiroaki.

:: Heart and Vessels, 巻 34, 番号 1, 22.01.2019, p. 141-150.

研究成果: ジャーナルへの寄稿記事

Uchiyama, Shinichiro ; Atarashi, Hirotsugu ; Inoue, Hiroshi ; Kitazono, Takanari ; Yamashita, Takeshi ; Shimizu, Wataru ; Ikeda, Takanori ; Kamouchi, Masahiro ; Kaikita, Koichi ; Fukuda, Koji ; Origasa, Hideki ; Shimokawa, Hiroaki. / Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study. :: Heart and Vessels. 2019 ; 巻 34, 番号 1. pp. 141-150.
@article{75b09c1403e64904b90e2fce30807a38,
title = "Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study",
abstract = "The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treated with rivaroxaban (10 mg/day, 43.5{\%}; 15 mg/day, 56.5{\%}) were followed for a mean period of 897.1 ± 206.8 days with a high follow-up rate (99.7{\%}). The primary prevention group comprised patients without history of ischemic stroke or TIA (n = 5546, 77.7{\%}), and the secondary prevention group comprised those with history of ischemic stroke or TIA (n = 1595, 22.3{\%}). In the primary and secondary prevention groups, the incidence rate of stroke or SE (primary efficacy endpoint) was 0.7 and 2.2{\%}/year, respectively (P < 0.001), and the incidence rate of major bleeding (primary safety endpoint) was 1.2 and 1.5{\%}/year, respectively (P = 0.132). For major bleeding events, the incidence rate of intracranial bleeding was 0.4 and 0.8{\%}/year (P = 0.002) in the primary and secondary prevention groups, respectively. This sub-analysis of the EXPAND Study showed that the Japan-specific dosages of rivaroxaban were effective and safe in Japanese NVAF patients with and those without ischemic stroke or TIA in routine clinical practice.",
author = "Shinichiro Uchiyama and Hirotsugu Atarashi and Hiroshi Inoue and Takanari Kitazono and Takeshi Yamashita and Wataru Shimizu and Takanori Ikeda and Masahiro Kamouchi and Koichi Kaikita and Koji Fukuda and Hideki Origasa and Hiroaki Shimokawa",
year = "2019",
month = "1",
day = "22",
doi = "10.1007/s00380-018-1219-0",
language = "English",
volume = "34",
pages = "141--150",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation

T2 - Sub-analysis of the EXPAND Study

AU - Uchiyama, Shinichiro

AU - Atarashi, Hirotsugu

AU - Inoue, Hiroshi

AU - Kitazono, Takanari

AU - Yamashita, Takeshi

AU - Shimizu, Wataru

AU - Ikeda, Takanori

AU - Kamouchi, Masahiro

AU - Kaikita, Koichi

AU - Fukuda, Koji

AU - Origasa, Hideki

AU - Shimokawa, Hiroaki

PY - 2019/1/22

Y1 - 2019/1/22

N2 - The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treated with rivaroxaban (10 mg/day, 43.5%; 15 mg/day, 56.5%) were followed for a mean period of 897.1 ± 206.8 days with a high follow-up rate (99.7%). The primary prevention group comprised patients without history of ischemic stroke or TIA (n = 5546, 77.7%), and the secondary prevention group comprised those with history of ischemic stroke or TIA (n = 1595, 22.3%). In the primary and secondary prevention groups, the incidence rate of stroke or SE (primary efficacy endpoint) was 0.7 and 2.2%/year, respectively (P < 0.001), and the incidence rate of major bleeding (primary safety endpoint) was 1.2 and 1.5%/year, respectively (P = 0.132). For major bleeding events, the incidence rate of intracranial bleeding was 0.4 and 0.8%/year (P = 0.002) in the primary and secondary prevention groups, respectively. This sub-analysis of the EXPAND Study showed that the Japan-specific dosages of rivaroxaban were effective and safe in Japanese NVAF patients with and those without ischemic stroke or TIA in routine clinical practice.

AB - The EXPAND Study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF). In this sub-analysis, we compared the differences in efficacy and safety between patients with and those without history of stroke or transient ischemic attack (TIA). This multicenter, prospective, non-interventional, observational, cohort study was conducted at 684 medical centers in Japan. A total of 7141 NVAF patients aged ≥ 20 years [mean age 71.6 ± 9.4 (SD) years] who were being or planned to be treated with rivaroxaban (10 mg/day, 43.5%; 15 mg/day, 56.5%) were followed for a mean period of 897.1 ± 206.8 days with a high follow-up rate (99.7%). The primary prevention group comprised patients without history of ischemic stroke or TIA (n = 5546, 77.7%), and the secondary prevention group comprised those with history of ischemic stroke or TIA (n = 1595, 22.3%). In the primary and secondary prevention groups, the incidence rate of stroke or SE (primary efficacy endpoint) was 0.7 and 2.2%/year, respectively (P < 0.001), and the incidence rate of major bleeding (primary safety endpoint) was 1.2 and 1.5%/year, respectively (P = 0.132). For major bleeding events, the incidence rate of intracranial bleeding was 0.4 and 0.8%/year (P = 0.002) in the primary and secondary prevention groups, respectively. This sub-analysis of the EXPAND Study showed that the Japan-specific dosages of rivaroxaban were effective and safe in Japanese NVAF patients with and those without ischemic stroke or TIA in routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85049561544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049561544&partnerID=8YFLogxK

U2 - 10.1007/s00380-018-1219-0

DO - 10.1007/s00380-018-1219-0

M3 - Article

VL - 34

SP - 141

EP - 150

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 1

ER -